stockrow
Friday 6 November 2026
Export GH’s income statement to Excel — free account
Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
150.48
2.95
−1.92%
Follow GH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
13.04 | 11.23 | 16.85 | 18.75 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(485.56) | (184.78) | (345.01) | (1,011.33) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
13.35 | 11.60 | 17.23 | 19.10 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(70.95) | (66.74) | (110.07) | (140.79) | |
EV/FCF |
(52.23) | (49.12) | (78.82) | (97.68) | |
Quick Ratio |
4.42 | 4.25 | 3.53 | 0.50 | |
Current Ratio |
4.84 | 4.68 | 4.03 | 3.60 | |
Net Debt/EBITDA |
(2.59) | (3.37) | (3.73) | 0.00 | |
Debt/Assets |
74.69% | 78.50% | 78.59% | 79.68% | |
Debt/Equity |
(15.14) | (8.30) | (6.74) | (5.45) | |
Asset Turnover |
0.56 | 0.66 | 0.73 | 0.81 | |
Operating CF/Net income |
0.21 | 0.59 | 0.48 | 0.19 | |
Capex/Depreciation |
(6.67) | (2.27) | (1.37) | 0.00 | |
Interest Coverage |
(102.38) | (90.09) | (95.93) | (98.71) | |
Research and Development Expense of Revenue |
34.94% | 30.18% | 28.82% | 27.93% | |
Selling, General and Administrative Expense of Revenue |
72.64% | 75.27% | 75.11% | 74.27% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
15.36% | 15.78% | 17.23% | 17.30% | |
Graham Net Nets |
(0.05) | (0.06) | (0.04) | (0.03) | |
Graham Number |
7.68 | 10.26 | 11.48 | 13.04 | |
Earnings Yield |
(3.24%) | (3.67%) | (2.33%) | (2.06%) | |
Free Cash Flow Yield |
(1.96%) | (2.10%) | (1.30%) | (1.04%) | |
Revenue per Share |
2.24 | 2.30 | 2.52 | 2.69 | |
Operating CF per Share |
(0.21) | (0.50) | (0.43) | (0.18) | |
Capex per Share |
(0.22) | (0.04) | (0.09) | (0.10) | |
Free Cash Flow per Share |
(0.43) | (0.54) | (0.52) | (0.28) | |
Cash per Share |
9.58 | 8.40 | 7.93 | 0.00 | |
Shareholders Equity per Share |
(0.79) | (1.38) | (1.68) | (2.05) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.79) | (1.38) | (1.68) | (2.05) | |
Free Cash Flow |
(54.22) | (71.20) | (69.54) | (37.19) | |
Working Capital |
1,163.32 | 1,075.36 | 1,025.68 | 970.24 | |
Capital Expenditures |
(27.85) | (5.58) | (11.76) | (13.48) | |
Net Current Asset Value |
(646.92) | (728.86) | (770.52) | (818.14) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.10 | 0.02 | 0.04 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
124.05 | 126.42 | 137.25 | 151.07 | |
Average Payables |
46.50 | 62.40 | 69.16 | 61.33 | |
Average Inventory |
78.48 | 80.55 | 94.76 | 91.99 | |
Average Assets |
1,749.63 | 1,629.76 | 1,622.15 | 1,581.21 | |
Average Common Equity |
(119.48) | (215.93) | (264.17) | (315.19) |
Columns are period end dates · fundamentals updated 5 Nov 2026